While ideally prophylactic HIV vaccines should elicit neutralizing and non-neutralizing antibodies capable of interrupting virus infection at the urogenital mucosa, the primary site of virus transmission through sexual contacts, the V1V2 vaccine formulations tested here, including the NE/IVT adjuvant designed specifically for mucosal delivery, elicited negligible vaginal IgG and IgA against V1V2 and Env. This evidence concerns the gene CD79A and viral infectious disease.